Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999936 | 1.00 | NR3C1 (0.64) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL9356884 | 0.91 | CYP19A1 (0.56) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL9356635 | 0.91 | CYP19A1 (0.56) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL9356926 | 0.89 | CYP19A1 (0.54) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL9360771 | 0.89 | CYP19A1 (0.53) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL9073294 | 0.88 | CYP19A1 (0.63) | NR3C1CYP19A1CYP17A1 | |
| SCHEMBL10708164 | 0.87 | CYP19A1 (0.62) | NR3C1CYP19A1CYP17A1 | |
| SCHEMBL8999931 | 0.86 | CYP19A1 (0.67) | NR3C1CYP19A1CYP17A1 | |
| SCHEMBL8668371 | 0.86 | CYP19A1 (0.54) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 | |
| SCHEMBL21541438 | 0.85 | NR3C1 (0.46) | NR3C1CYP19A1LMNASMN1; SMN2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023049689-A1 | TREATMENT OF CONGENITAL ADRENAL HYPOPLASIA | REVERAGEN BIOPHARMA, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-8334279-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | VALIDUS GENETICS (US) | 2012-12-18 | — | — | US | disclosed |
| US-8207151-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | Validus Biopharma Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207151-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | Validus Biopharma Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2444092-A1 | Non-hormonal steroid modulators of nf-kb for treatment of disease | Validus Biopharma, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2011127048-A2 | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885CYP19A1 61/4885LMNA 2288/4885 |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885CYP19A1 410/4885LMNA 671/4885 |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885CYP19A1 410/4885LMNA 671/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NR3C1 10/4885CYP19A1 88/4885LMNA 2201/4885 |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885CYP19A1 410/4885LMNA 671/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885CYP19A1 410/4885LMNA 671/4885 |
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885CYP19A1 61/4885LMNA 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.